Archives

by in
Entry Author Date Location
Akebia, Trading M&A For an IPO, Follows Fast in Anemia Drug Race 06/09/14 Boston
Enanta, No Longer Obscure, Seeks Slice of Big Hepatitis C Market 01/24/14 Boston
Madison Vaccines Closes $8M Series A Round for Prostate Treatment 01/13/14 Wisconsin
Epizyme Prices IPO at $15 Per Share, Begins Trading Friday 05/30/13 Boston
Pfizer Yields to Rivals in Hep C Drug Race 03/13/13 New York
Adimab Grows Up, Looks to Pay Off the VCs In Unusual Way 02/22/13 Boston
Corporate Compliance Programs: The Importance of Being Effective 02/15/13 National
Crescendo Bioscience Snags $28M For Arthritis Test 01/03/13 San Francisco
Aastrom Names New Interim CEO, Mayleben To Remain Active in Fundraising 12/14/12 Detroit
East Coast Life Sciences Roundup: Bristol-Myers, Alnylam, Merck, & More 11/16/12 Boston
Hepatitis C Treatments from Gilead, Abbott Wow Liver Meeting 11/13/12 Boston
East Coast Life Sciences Roundup: Vertex, Thermedical, More 11/02/12 Boston
Seattle Genetics Gets $25M in Broader Abbott Deal 10/23/12 Seattle
Zymeworks Hits Antibody Drug Milestone For Merck, Raises $11M 09/06/12 Seattle
Would Longer Drug Patents Really Lead to Lower Drug Prices? 09/05/12 Seattle
Nodality Snags Pfizer Deal to Improve Autoimmune R&D, Diagnostics 08/09/12 San Francisco
Clash of the BioPharma Titans Looms Over Biosimilars 06/25/12 National
Why Would a Biotech Company Go the Trouble of Changing Its Name? 06/04/12 National
What Are the Hottest Targets in Biotech Today? 04/23/12 National
Abbott’s Humira, the 3rd-in-Class Drug That Toppled Lipitor as No. 1 04/16/12 National
Wayne State Hires Former Pharma Exec to Lead Tech Commercialization Efforts 02/02/12 Detroit
Vertex Names Jeff Leiden as New CEO, Staring Down Tough Competition 12/15/11 Boston
ImmusanT, Developing Celiac Disease Treatments, Closes $20M Series A 12/13/11 Boston
The Hepatitis C Market: Biotech’s Version of the Daytona 500 12/12/11 National
The Cancer Drug Dark Ages Are Coming to an End 10/31/11 National
Light Sciences Stumbles, Cardiac Dimensions Gets EU OK, Immune Design Pockets $11M, & More Seattle-Area Life Sciences News 10/06/11 Seattle
Cardiac Dimensions Wins EU Approval for Heart Failure Device, Aims for Market in 2012 09/29/11 Seattle
Crescendo Bioscience Nabs $56M to Help Personalize Rheumatoid Arthritis Therapy 09/08/11 San Francisco
Allozyne’s Backdoor IPO, Sound Pharma Fights iPod Deafness, Mirina Vs. Marina Ends, & More Seattle-Area Life Sciences News 06/23/11 Seattle
Alder Gets $15M From Bristol 06/20/11 Seattle
Page 1 of 4 next page »